2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. DNA/RNA Synthesis

DNA/RNA Synthesis

DNA/RNA Synthesis

Related Products

PDF 1.61 MB

RNA synthesis, which is also called DNA transcription, is a highly selective process. Transcription by RNA polymerase II extends beyond RNA synthesis, towards a more active role in mRNA maturation, surveillance and export to the cytoplasm.

Single-strand breaks are repaired by DNA ligase using the complementary strand of the double helix as a template, with DNA ligase creating the final phosphodiester bond to fully repair the DNA.DNA ligases discriminate against substrates containing RNA strands or mismatched base pairs at positions near the ends of the nickedDNA. Bleomycin (BLM) exerts its genotoxicity by generating free radicals, whichattack C-4′ in the deoxyribose backbone of DNA, leading to opening of the ribose ring and strand breakage; it is an S-independentradiomimetic agent that causes double-strand breaks in DNA.

First strand cDNA is synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis is subsequently performed using DNA Polymerase I and RNase H. The remaining overhangs are converted into blunt ends using exonuclease/polymerase activity. After adenylation of the 3′ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure is ligated to prepare the samples for hybridization. Cell cycle and DNA replication are the top two pathways regulated by BET bromodomain inhibition. Cycloheximide blocks the translation of mRNA to protein.

DNA/RNA Synthesis Isoform Specific Products:

DNA/RNA Synthesis Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16350
    BOLD-100
    		Inhibitor
    BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu.
    BOLD-100
  • HY-144256
    CHD1Li 6.11
    		Inhibitor 99.54%
    CHD1Li 6.11 is a potent and orally active Chromodomain Helicase DNA Binding Protein 1 Like (CHD1L) (oncogenic gene) inhibitor (IC50 = 3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 can inhibit EMT, induce mesenchymal-epithelial transition (reverse EMT) and promote apoptosis in tumor organoid models. CHD1Li 6.11 can be used for the research of cancer, such as colorectal cancer.
    CHD1Li 6.11
  • HY-101400A
    Deoxycytidine triphosphate trisodium solution (100 mM)
    		Activator 99.31%
    Deoxycytidine triphosphate trisodium (dCTP trisodium) solution (100 mM) is a nucleoside triphosphate that can be used for DNA synthesis. Deoxycytidine triphosphate trisodium salt has many applications, such as real-time PCR, cDNA synthesis, and DNA sequencing.
    Deoxycytidine triphosphate trisodium solution (100 mM)
  • HY-15588
    L189
    		Inhibitor 98.0%
    L189 is a DNA ligase inhibitor. L189 has inhibition effect for DNA Ligase I, III and IV with IC50 values of 5 μM, 9 μM and 5 μM, respectively. L189 has no cytotoxicity and individually increase cell death. L189 can be used for the research of cancer.
    L189
  • HY-16200
    Ethynylcytidine
    		Inhibitor 99.86%
    Ethynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis, inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancer. Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ethynylcytidine
  • HY-122234
    VPC-18005
    		Inhibitor 99.80%
    VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain, and disrupts the ERG binding to DNA. VPC-18005 is a potent inhibitor of luciferase activity.
    VPC-18005
  • HY-147918
    Anticancer agent 73
    		Inhibitor 99.92%
    Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo.
    Anticancer agent 73
  • HY-12429
    Beclabuvir
    		99.94%
    Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM.
    Beclabuvir
  • HY-141867
    Z-FF-FMK
    		Inhibitor
    Z-FF-FMK (Z-Phe-Phe-FMK) is a cell-permeable, irreversible, and cysteine protease inhibitor targeting cathepsin-L. Z-FF-FMK inhibits angiotensin II-induced MEK activation in vascular walls, aortic medial remodeling, blood pressure elevation, and upregulation of cystatin C in aortic walls. Z-FF-FMK prevents β-amyloid-mediated caspase-3 activation, poly (ADP-ribose) polymerase cleavage, DNA fragmentation, and apoptosis of cortical neurons (apoptosis). Z-FF-FMK can be used in research related to hypertension and Alzheimer's disease.
    Z-FF-FMK
  • HY-B1002
    Oxolinic acid
    		Inhibitor 98.97%
    Oxolinic acid is an antibiotic against both Gram-negative and Gram-positive bacteria. Oxolinic acid can be used for the research of acute and chronic urinary tract infections. Oxolinic acid is a DNA/RNA synthesis inhibitor. Oxolinic acid acts a dopamine uptake inhibitor and stimulants locomotor effect in mice.
    Oxolinic acid
  • HY-E70086
    Taq DNA polymerase
    Taq DNA polymerase is a thermostable DNA polymerase that can be used in PCR.
    Taq DNA polymerase
  • HY-153736
    NSC 194308
    		99.86%
    NSC 194308, a U2AF2-RNA complexes enhancer, increases association of the U2AF1-U2AF2-SF1-splice site RNA complex by binding a site between the U2AF2 RNA recognition motifs (RRM1 and RRM2). NSC 194308 inhibits pre-mRNA splicing by stalling spliceosome assembly at the point where U2AF helps recruit U2 snRNP to the branchpoint. NSC 194308 enhances the binding of pre-mRNA to U2AF2, selectively triggering cell death in leukemia cell lines containing spliceosome mutations.
    NSC 194308
  • HY-100758
    FUBP1-IN-1
    		Inhibitor 99.72%
    FUBP1-IN-1 is a potent FUSE binding protein 1 (FUBP1) inhibitor which interferes with the binding of FUBP1 to its single stranded target DNA FUSE sequence , with an IC50 value of 11.0 μM.
    FUBP1-IN-1
  • HY-120836
    AOH1160
    		Inhibitor 98.56%
    AOH1160 is a potent oral small molecule proliferating cell nuclear antigen (PCNA) inhibitor that interferes with DNA replication, blocks homologous recombination-mediated DNA repair, leads to cell cycle arrest and induces apoptosis.
    AOH1160
  • HY-B0268A
    Enoxacin hydrate
    		Inhibitor 99.85%
    Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
    Enoxacin hydrate
  • HY-160007
    DHX9-IN-3
    		Inhibitor 98.67%
    DHX9-IN-3 (Compound 621) is an inhibitor of ATP-dependent RNA helicase A (DHX9). DHX9-IN-3 has an IC50 of 8.7 nM for anti-proliferation in LS411N cells. DHX9-IN-3 can be used in the study of cancer.
    DHX9-IN-3
  • HY-126490
    Phleomycin
    		Inhibitor
    Phleomycin is a copper-dependent DNA damaging agent and antibiotic with antitumor activity. Phleomycin binds to DNA and produces ROS in the presence of reducing agents (such as dithiothreitol and glutathione), inducing single-strand and double-strand breaks in DNA. Phleomycin can induce cell apoptosis or mutation and is widely used in cancer inhibition, microbial genetic transformation (as a screening marker to improve fungal transformation efficiency) and DNA repair mechanism research.
    Phleomycin
  • HY-157783
    Dencatistat
    		Inhibitor 99.87%
    Dencatistat is a CTP synthetase 1 (b) inhibitor. CTPS1 is a key rate-limiting enzyme that catalyzes the conversion of UTP to CTP. Dencatistat can be used for research on lymphoma.
    Dencatistat
  • HY-125209
    TH5427
    		Inhibitor 99.92%
    TH5427 is a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism. TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. NUDT5 is recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells.
    TH5427
  • HY-145685
    RECQL5-IN-1
    		Inhibitor 98.40%
    RECQL5-IN-1 (Compound 4a) acts as an orally effective RECQL5 inhibitor (targeting both enzymatic and nonenzymatic domain). RECQL5-IN-1 is a potent inhibitor of RECQL5 helicase activity (IC50=46.3 nM), stabilizes the interaction between RECQL5-RAD51 proteins, causes RAD51 aggregation and homologous recombination repair (HRR) inhibition, thereby exhibiting selective cytotoxicity in RECQL5-expressing cancer cells.
    RECQL5-IN-1
Cat. No. Product Name / Synonyms Application Reactivity
DNA/RNA Synthesis Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.